Clarity Pharmaceuticals Ltd
ASX:CU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Clarity Pharmaceuticals Ltd
Total Equity
Clarity Pharmaceuticals Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Equity
AU$90.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Equity
-AU$18.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Equity
AU$370.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Equity
AU$338.5m
|
CAGR 3-Years
101%
|
CAGR 5-Years
69%
|
CAGR 10-Years
37%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Total Equity
AU$56.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
|
Nyrada Inc
ASX:NYR
|
Total Equity
AU$9.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
See Also
What is Clarity Pharmaceuticals Ltd's Total Equity?
Total Equity
90.2m
AUD
Based on the financial report for Jun 30, 2025, Clarity Pharmaceuticals Ltd's Total Equity amounts to 90.2m AUD.
What is Clarity Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
62%
Over the last year, the Total Equity growth was -38%. The average annual Total Equity growth rates for Clarity Pharmaceuticals Ltd have been -1% over the past three years , 62% over the past five years .
